Early use of high efficacy therapies in pediatric forms of relapsing-remitting multiple sclerosis: A real-life...

Area of Science:

• Neurology
• Pediatric Neurology
• Immunology

Background:

• Pediatric multiple sclerosis (MS) exhibits higher disease activity compared to adult forms.
• Limited research exists on the comparative effectiveness of various therapeutic strategies in pediatric MS.
• This study addresses the need to evaluate treatment efficacy in young MS patients.

Purpose of the Study:

• To compare the effectiveness of early high-efficacy therapies (HETs) versus moderate-efficacy therapies (METs) in children diagnosed with MS.
• To assess the impact of early treatment choices on disease activity and disability progression in pediatric MS.

Main Methods:

• An observational study conducted across four French hospital centers over a decade.
• Included patients diagnosed with pediatric MS.
• Classified METs (interferon β-1a, glatiramer acetate, dimethyl fumarate, teriflunomide) and HETs (fingolimod, natalizumab, ocrelizumab, alemtuzumab).
• Primary endpoint: new relapse occurrence; Secondary endpoint: Expanded Disability Status Scale (EDSS) worsening.

Main Results:

• Sixty-four pediatric MS patients were analyzed (80% female, mean age 15.5 years).
• At 6.5 years, the relapse-free probability was 23.3% for METs versus 90.9% for HETs (p=0.013).
• No significant difference was observed in the probability of no EDSS worsening between the two treatment groups.

Conclusions:

• Pediatric MS patients initiating METs demonstrated significantly higher clinical disease activity compared to those starting early with HETs.
• Early initiation of HETs may lead to superior disease control in pediatric MS.
• The effect of early HETs on EDSS worsening in pediatric MS remains inconclusive and warrants further study.